VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...
One woman shares her story of hope living with a rare and aggressive brain cancer. Jennifer's* story begins in a small town ...
The chondrosarcoma market is anticipated to increase during the forecast period (2026--2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies ...
Pasithea Therapeutics Corp. ( KTTA) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 4:00 PM EST ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
(DecisionDx-Melanoma, TissueCypher) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast ...
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or ...
Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results